Adults 21 to 50, any sex, with Alcohol Drinking. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Abnormal Labs and Adverse EventsPrimary· Day 10
Number of participants (at Day 10; after both alcohol sessions and completed course of mavoglurant) with abnormal lab values or adverse events related to the interaction of alcohol and mavoglurant
Number of participants that reported Adverse Event(s)
Group
Value
95% CI
200 mg Mavoglurant
9
Placebo
8
Abnormal/Clinically Significant lab values after Mavoglurant and alcohol administration
Group
Value
95% CI
200 mg Mavoglurant
0
Placebo
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected over the course of the study from randomization to the 1 week follow-up visit; approximately 3 weeks..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this alcohol-interaction pilot study is to provide information on the effect of mavoglurant on the pharmacokinetics of alcohol and on alcohol responses, including stimulation, sedation, intoxication, body sway and physiological responses. The investigators propose to test the effects of 200 mg mavoglurant versus placebo on alcohol related responses. This is a between subjects double blind randomized design in which the investigators plan to run 40 subjects to obtain 28 completers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06136195 — Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
· Phase 1
· recruiting
Other recruiting trials for Alcohol Drinking
Currently open trials in the same condition.
NCT07415707 — The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in N
· NA
· recruiting
NCT06815237 — Effects of Ketone Supplement and Alcohol on Brain Metabolism
· Phase 2, PHASE3
· recruiting
NCT05363878 — Development of a Culturally Grounded, Trauma-Informed Alcohol Intervention With a Reserve-Dwelling First Nation Group
· NA
· recruiting
NCT06309134 — The Healthy Families Bright Futures Program
· NA
· recruiting
Other Yale University trials
Trials by the same sponsor.
NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking
· Phase 2
· not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing
· NA
· not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S
· NA
· not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa
· Phase 1, PHASE2
· not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 6 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03327792.